Nurix Therapeutics (NRIX) investor relations material

Executive summary

• Entered a global collaboration with Roche for bexobrutideg, including a $700M upfront payment and up to $2.3B in milestones, covering co-development and co-commercialization in malignant hematology, immunology, and neurology.

• Focused on targeted protein degradation medicines for cancer and inflammatory diseases, leveraging an AI-integrated discovery platform and multiple strategic collaborations with Sanofi, Gilead, and Pfizer.

• Lead clinical programs include bexobrutideg (NX-5948), zelebrudomide (NX-2127), and NX-1607, all in early clinical development stages.

• Presented updated clinical data at EHA 2026 showing strong efficacy and tolerability for bexobrutideg in CLL; expanded development into chronic spontaneous urticaria and multiple sclerosis.

Financial highlights

• Revenue for Q2 2026 was $9.0M, down from $44.1M year-over-year; six-month revenue was $15.3M, down from $62.5M.

• Net loss for the quarter was $89.5M, compared to $43.5M year-over-year; six-month net loss was $176.7M, compared to $99.8M.

• Cash, cash equivalents, and marketable securities totaled $443.5M as of May 31, 2026, with pro-forma cash of ~$1.14B including the Roche upfront payment.

• Accumulated deficit reached $1.2B as of May 31, 2026.

Outlook and guidance

• Anticipates receiving the $700M upfront payment from Roche in Q3 2026, sufficient to fund operations for at least the next 12 months.

• Plans to initiate Phase 2 trials in CSU and MS and a Phase 3 confirmatory trial in CLL in mid-2026.

• Substantial additional funding will be needed to support long-term plans and commercialization; anticipates continued operating losses until significant product sales are achieved.